Search

Blocking a molecule that draws sensory nerves into musculoskeletal injuries prevents heterotopic ossification (HO), a process in which bone abnormally grows in soft tissue during healing

Two genes working in tandem play a critical role in shaping the identity and behavior of prostate cancer cells and their response to treatment, UT Southwestern Medical Center researchers report.

Children's HealthSM and UT Southwestern Medical Center on Wednesday announced a historic gift of $100 million from the Jean and Mack Pogue family in support of the $5 billion transformative new Dallas pediatric campus, unveiled earlier this year. The gift from the Pogue Foundation is one of only

In Memoriam: Jonathan W. Uhr, M.D., renowned immunologist and longtime Chair of Microbiology

Reuben Arasaratnam, M.D., M.P.H., Assistant Professor of Internal Medicine at UT Southwestern, has been named one of 11 2022 Scholars in Diagnostic Excellence by the National Academy of Medicine (NAM).

Interstitial pneumonia with autoimmune features (IPAF) is a disease with many possible causes and no standard of care, making it particularly difficult to treat. While immunosuppressant drugs are primarily prescribed, they don’t work for all patients.

A new initiative funded by The University of Texas System and the state of Texas seeks to improve care for trauma patients.

The number of mutations in the DNA of cancerous tumors may not be an indicator of how well patients will respond to immune checkpoint inhibitors (ICIs), a commonly prescribed type of immunotherapy, a team led by UT Southwestern Medical Center reported in a retrospective study.

At exactly 11 a.m. Friday, surrounded by family, friends, and mentors, 224 members of UT Southwestern Medical School’s Class of 2024 – who all embarked on their medical education during the height of the COVID-19 pandemic – learned where they will continue their medical training.

– In a groundbreaking phase one clinical trial led by UT Southwestern Medical Center, a short interfering RNA (siRNA) drug directed to tumor cells, ARO-HIF2, effectively disrupted HIF2α, a key driver of clear cell renal cell carcinoma (ccRCC).